Literature DB >> 23733481

European drug agency's attempts to improve transparency stalled by legal action from two US drug companies.

Clare Dyer.   

Abstract

Mesh：

Year:  2013        PMID： 23733481     DOI： 10.1136/bmj.f3588

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

Review 1.  Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials.

Authors:  Alex Hodkinson; Carrol Gamble; Catrin Tudur Smith
Journal:  Trials       Date:  2016-04-22       Impact factor: 2.279

Review 2.  Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.

Authors:  Emma Maund; Britta Tendal; Asbjørn Hróbjartsson; Karsten Juhl Jørgensen; Andreas Lundh; Jeppe Schroll; Peter C Gøtzsche
Journal:  BMJ       Date:  2014-06-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.